Jennison Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Jennison Associates's VRTX Position: Q2 2026 in Review
Jennison Associates increased its Vertex Pharmaceuticals (VRTX) stake by 9.4% in Q2 2026, buying an estimated $115M and bringing the position to 2,998,530 shares worth $1.49B. The position accounts for 0.89% of the portfolio, ranked #26.
Jennison Associates first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.74B in Q2 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Jennison Associates held 2,998,530 shares of Vertex Pharmaceuticals worth $1.49B as of Q2 2026.
- Jennison Associates bought 258,471 Vertex Pharmaceuticals shares in Q2 2026, an estimated $115M.
- Vertex Pharmaceuticals made up 0.89% of Jennison Associates's portfolio in Q2 2026, its #26 holding.
- Jennison Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Jennison Associates's Vertex Pharmaceuticals position peaked at $2.74B in Q2 2025.
- 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.